FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes.
The identification of fusin and other chemokine receptors as coreceptors for HIV-1 has renewed the interest in agents that may prevent viral entry. Polyanionic compounds such as dextran sulfate, curdian sulfate, and suramin act on the V3 loop of the viral envelope and may prevent its interaction with fusin. These agents show activity against a wide range of HIV-1 strains, but have undesirable circulating half-life, bioavailability, and toxicity. We have developed a small molecule inhibitor of HIV-1 that has several advantages over these other agents. FP-21399 is a novel compound of the bis(disulfonaphthalene) dimethoxybenzene class that blocks entry of HIV into CD4+ cells and blocks fusion of infected and noninfected CD4+ cells. This compound only weakly inhibits binding of CD4 and gp120, at concentrations much greater than are required to block viral entry. Furthermore, FP-21399 can block the interaction between gp120 and antibodies directed against the V3 loop, but does not block binding of antibodies directed against the V4 loop. Animal studies demonstrate that FP-21399 is concentrated in lymph nodes, making it a promising compound for anti-HIV therapy. In SCID mice reconstituted with human immune cells, maintenance of HIV-1 infection was blocked by a 5-day treatment with low doses of FP-21399, suggesting that lymph node accumulation may contribute to antiviral activity. Finally, attempts to generate drug-resistant virus in cell culture resulted in only weakly resistant variants with IC90 values that are much lower than concentrations of FP-21399 found in lymph nodes.
Ono
M
M
Fuji ImmunoPharmaceuticals Corp., Lexington, MA 02173, USA.
Wada
Y
Y
Wu
Y
Y
Nemori
R
R
Jinbo
Y
Y
Wang
H
H
Lo
K M
KM
Yamaguchi
N
N
Brunkhorst
B
B
Otomo
H
H
Wesolowski
J
J
Way
J C
JC
Itoh
I
I
Gillies
S
S
Chen
L B
LB
D000818:Animals; D019380:Anti-HIV Agents / Q000494:pharmacology*; D001709:Biotechnology; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000821:virology; D002460:Cell Line; D002722:Chlorobenzenes / Q000493:pharmacokinetics / Q000494:pharmacology*; D004285:Dogs; D004352:Drug Resistance, Microbial / Q000235:genetics; D015686:Gene Products, env / Q000037:antagonists & inhibitors / Q000502:physiology; D014644:Genetic Variation; D015699:HIV Envelope Protein gp120 / Q000187:drug effects / Q000502:physiology; D015658:HIV Infections / Q000517:prevention & control; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D006801:Humans; D008198:Lymph Nodes / Q000378:metabolism; D008297:Male; D008561:Membrane Fusion / Q000187:drug effects*; D051379:Mice; D016513:Mice, SCID; D009281:Naphthalenes / Q000493:pharmacokinetics / Q000494:pharmacology*; D010446:Peptide Fragments / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley
D019380:Anti-HIV Agents; D002722:Chlorobenzenes; D015686:Gene Products, env; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D009281:Naphthalenes; D010446:Peptide Fragments; C106790:FP 21399